HomeCompareCZAR vs CL

CZAR vs CL: Dividend Comparison 2026

CZAR yields 1.56% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CL wins by $18.9K in total portfolio value
10 years
CZAR
CZAR
● Live price
1.56%
Share price
$30.06
Annual div
$0.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$172.87
Full CZAR calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — CZAR vs CL

📍 CL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCZARCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CZAR + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CZAR pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CZAR
Annual income on $10K today (after 15% tax)
$132.80/yr
After 10yr DRIP, annual income (after tax)
$146.94/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, CL beats the other by $4,444.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CZAR + CL for your $10,000?

CZAR: 50%CL: 50%
100% CL50/50100% CZAR
Portfolio after 10yr
$31.4K
Annual income
$2,787.42/yr
Blended yield
8.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

CZAR
No analyst data
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CZAR buys
0
CL buys
0
No recent congressional trades found for CZAR or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCZARCL
Forward yield1.56%2.43%
Annual dividend / share$0.47$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$21.9K$40.8K
Annual income after 10y$172.87$5,401.96
Total dividends collected$1.7K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CZAR vs CL ($10,000, DRIP)

YearCZAR PortfolioCZAR Income/yrCL PortfolioCL Income/yrGap
1← crossover$10,856$156.23$11,012$312.01$156.00CL
2$11,775$158.52$12,196$412.95$421.00CL
3$12,760$160.68$13,599$549.66$839.00CL
4$13,815$162.73$15,288$736.64$1.5KCL
5$14,947$164.67$17,353$995.28$2.4KCL
6$16,160$166.50$19,926$1,357.80$3.8KCL
7$17,459$168.23$23,194$1,873.82$5.7KCL
8$18,852$169.87$27,439$2,621.52$8.6KCL
9$20,343$171.42$33,088$3,727.38$12.7KCL
10$21,939$172.87$40,806$5,401.96$18.9KCL

CZAR vs CL: Complete Analysis 2026

CZARStock

CZAR aims to mirror the performance of the Solactive Natural Monopoly Index, which includes global companies perceived to have a strong competitive edge within their sectors. The fund is focused on large- and mid-cap companies that meet certain requirements. This includes being part of a broader Solactive index aimed at Developed Markets, maintaining an average daily value traded, and meeting volume and free-float market capitalization percentage criteria. Stock selection for the fund is then based on fundamental financial metrics such as sales, profit margin, return on equity, inventory/total assets, and intangible assets/total assets. The top five firms within each sector are then chosen for the index. Weighting is designed to be sector-neutral, taking into consideration the free-float market capitalization of the index. Securities are then weighted equally within sectors, ensuring balanced exposure. CZAR is rebalanced seven business days after the semi-annual Selection Days in June and December.

Full CZAR Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this CZAR vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CZAR vs SCHDCZAR vs JEPICZAR vs OCZAR vs KOCZAR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.